DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
78.92
+4.62 (6.22%)
At close: Sep 3, 2025, 4:00 PM
79.18
+0.26 (0.33%)
Pre-market: Sep 4, 2025, 8:33 AM EDT
DexCom Revenue
DexCom had revenue of $1.16B in the quarter ending June 30, 2025, with 15.21% growth. This brings the company's revenue in the last twelve months to $4.30B, up 9.30% year-over-year. In the year 2024, DexCom had annual revenue of $4.03B with 11.34% growth.
Revenue (ttm)
$4.30B
Revenue Growth
+9.30%
P/S Ratio
7.19
Revenue / Employee
$417,553
Employees
10,300
Market Cap
30.95B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
DXCM News
- 15 hours ago - DexCom, Inc. (DXCM) Presents At 2025 Wells Fargo Healthcare Conference (Transcript) - Seeking Alpha
- 7 days ago - DexCom, GE, SLB: Why Experts Rate These Stocks at Strong Buy - Kiplinger
- 9 days ago - Dexcom Announces Upcoming Conference Presentations - Business Wire
- 4 weeks ago - 10 stocks favored to gain up to 30% in a sector that has missed this year's rally - Market Watch
- 5 weeks ago - DexCom, Inc. (DXCM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Dexcom beats estimates for quarterly results, names new CEO - Reuters
- 5 weeks ago - Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan - Business Wire
- 5 weeks ago - Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program - Business Wire